| Abigail F Donnelly, MD | |
|
755 W Carmel Dr, Suite 101, Carmel, IN 46032-5877 | |
| (317) 846-2396 | |
| (317) 846-1699 |
| Full Name | Abigail F Donnelly |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 14 Years |
| Location | 755 W Carmel Dr, Carmel, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760700918 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 01076565A (Indiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Forefront Dermatology | 3779471701 | 474 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
A potential new way to fight obesity-related illness has been uncovered, thanks to serendipitous research led by investigators at the Case Western Reserve University School of Medicine.
A new study sheds light on why individuals who inherit a particular family of mutations have a high risk of developing a very aggressive form of breast cancer. The research, published by Cell Press on February 4th in the journal Cell Stem Cell, shows that breast tissue cells from these individuals make abnormal cell-fate decisions even before cancer develops and provides exciting new insights into the mechanisms behind one of the most lethal types of breast cancer.
Sun Pharma today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the Eastern District of Michigan against Eli Lily and Co. finding certain claims of U.S. Patent No. 5,464,826 ("'826 patent") invalid. The appeal arose out of a lawsuit that Eli Lilly filed against Sun Pharma in connection with Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gemzar®.
› Verified 5 days ago
| Entity Name | Forefront Dermatology Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659796225 PECOS PAC ID: 3779471701 Enrollment ID: O20140425001640 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
A potential new way to fight obesity-related illness has been uncovered, thanks to serendipitous research led by investigators at the Case Western Reserve University School of Medicine.
A new study sheds light on why individuals who inherit a particular family of mutations have a high risk of developing a very aggressive form of breast cancer. The research, published by Cell Press on February 4th in the journal Cell Stem Cell, shows that breast tissue cells from these individuals make abnormal cell-fate decisions even before cancer develops and provides exciting new insights into the mechanisms behind one of the most lethal types of breast cancer.
Sun Pharma today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the Eastern District of Michigan against Eli Lily and Co. finding certain claims of U.S. Patent No. 5,464,826 ("'826 patent") invalid. The appeal arose out of a lawsuit that Eli Lilly filed against Sun Pharma in connection with Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gemzar®.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Abigail F Donnelly, MD 801 York St, Manitowoc, WI 54220-4630 Ph: (920) 663-9016 | Abigail F Donnelly, MD 755 W Carmel Dr, Suite 101, Carmel, IN 46032-5877 Ph: (317) 846-2396 |
News Archive
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.
A potential new way to fight obesity-related illness has been uncovered, thanks to serendipitous research led by investigators at the Case Western Reserve University School of Medicine.
A new study sheds light on why individuals who inherit a particular family of mutations have a high risk of developing a very aggressive form of breast cancer. The research, published by Cell Press on February 4th in the journal Cell Stem Cell, shows that breast tissue cells from these individuals make abnormal cell-fate decisions even before cancer develops and provides exciting new insights into the mechanisms behind one of the most lethal types of breast cancer.
Sun Pharma today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the Eastern District of Michigan against Eli Lily and Co. finding certain claims of U.S. Patent No. 5,464,826 ("'826 patent") invalid. The appeal arose out of a lawsuit that Eli Lilly filed against Sun Pharma in connection with Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gemzar®.
› Verified 5 days ago
Laryn K Steadman, MD Dermatology Medicare: Medicare Enrolled Practice Location: 755 W Carmel Dr Ste 101, Carmel, IN 46032 Phone: 317-846-2396 Fax: 317-846-1699 | |
Mary J Tempel, N.P. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 11900 N Pennsylvania St, #202, Carmel, IN 46032 Phone: 317-926-3739 Fax: 317-921-7478 | |
Nico Mousdicas, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 755 W Carmel Dr, Suite 101, Carmel, IN 46032 Phone: 317-846-2396 Fax: 317-846-1699 | |
Dr. Andrew T Bridge, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 13000 N Meridian St Ste 101, Carmel, IN 46032 Phone: 317-208-3813 Fax: 317-208-3815 | |
Robert Patrick Daze, DO Dermatology Medicare: Medicare Enrolled Practice Location: 755 W Carmel Dr Ste 101, Carmel, IN 46032 Phone: 317-846-2396 Fax: 317-846-1699 | |
Ross Matthew Levy, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 13450 N Meridian St, Suite 355, Carmel, IN 46032 Phone: 317-582-8484 | |
Lisa Edwards Trivedi, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 Lakefront Ct, Carmel, IN 46032 Phone: 317-926-3739 |